|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 April 2001, Vol. 97, No. 8, pp. 2366-2373
IMMUNOBIOLOGY
Primary human herpesvirus 8 infection generates a broadly
specific CD8+ T-cell response to viral lytic
cycle proteins
Qiong J. Wang,
Frank J. Jenkins,
Lisa P. Jacobson,
Lawrence A. Kingsley,
Richard D. Day,
Zhi-Wei Zhang,
Yuan-Xiang Meng,
Philip E. Pellet,
Konstantin G. Kousoulas,
Abolghasem Baghian, and
Charles R. Rinaldo Jr
From the Department of Infectious Diseases and
Microbiology and the Department of Biostatistics, Graduate School of
Public Health, and the Department of Pathology, School of Medicine,
University of Pittsburgh, Pittsburgh, Pennsylvania; Department of
Epidemiology, The Johns Hopkins University, Baltimore, Maryland;
Centers for Disease Control and Prevention, Atlanta, Georgia; and
School of Veterinary Medicine, Louisiana State University, Baton Rouge,
Louisiana.
Human herpesvirus 8 (HHV-8) is a recently discovered
gammaherpesvirus that is the etiologic agent of Kaposi sarcoma (KS). The natural history of primary HHV-8 infection, including clinical outcome and host immune responses that may be important in preventing disease related to HHV-8, has not been elucidated. The present study
characterized the clinical, immunologic, and virologic parameters of
primary HHV-8 infection in 5 cases detected during a 15-year longitudinal study of 108 human immunodeficiency virus type 1 seronegative men in the Multicenter AIDS Cohort Study. Primary HHV-8
infection was associated with mild, nonspecific signs and symptoms of
diarrhea, fatigue, localized rash, and lymphadenopathy. There were no
alterations in numbers of CD4+ or CD8+ T cells
or CD8+ T-cell interferon  (IFN-) production to
mitogen or nominal antigen. CD8+ cytotoxic T-lymphocyte
precursor (CTLp) and IFN- reactivity were detected during primary
HHV-8 infection, with broad specificity to 5 lytic cycle proteins of
HHV-8 encoded by open reading frame 8 (ORF 8; glycoprotein B homolog of
Epstein-Barr virus), ORF 22 (gH homolog), ORF 25 (major capsid protein
homolog), ORF 26 (a minor capsid protein homolog), or ORF 57 (an early
protein homolog), in association with increases in serum antibody
titers and appearance of HHV-8 DNA in blood mononuclear cells.
CD8+ T-cell responses to HHV-8 decreased by 2 to 3 years
after primary infection. This antiviral T-cell response may control
initial HHV-8 infection and prevent development of disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. R. Hensler, G. Rappocciolo, C. R. Rinaldo, and F. J. Jenkins
Cytokine production by human herpesvirus 8-infected dendritic cells
J. Gen. Virol.,
January 1, 2009;
90(1):
79 - 83.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Barcy, S. C. De Rosa, J. Vieira, K. Diem, M. Ikoma, C. Casper, and L. Corey
{gamma}{delta}+ T Cells Involvement in Viral Immune Control of Chronic Human Herpesvirus 8 Infection
J. Immunol.,
March 1, 2008;
180(5):
3417 - 3425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Guihot, E. Oksenhendler, L. Galicier, A.-G. Marcelin, L. Papagno, A.-S. Bedin, F. Agbalika, N. Dupin, J. Cadranel, B. Autran, et al.
Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells
Blood,
February 1, 2008;
111(3):
1387 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Stebbing, A. Sanitt, A. Teague, T. Powles, M. Nelson, B. Gazzard, and M. Bower
Prognostic Significance of Immune Subset Measurement in Individuals With AIDS-Associated Kaposi's Sarcoma
J. Clin. Oncol.,
June 1, 2007;
25(16):
2230 - 2235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bihl, M. Narayan, J. V. Chisholm III, L. M. Henry, T. J. Suscovich, E. E. Brown, T. M. Welzel, D. E. Kaufmann, T. M. Zaman, S. Dollard, et al.
Lytic and Latent Antigens of the Human Gammaherpesviruses Kaposi's Sarcoma-Associated Herpesvirus and Epstein-Barr Virus Induce T-Cell Responses with Similar Functional Properties and Memory Phenotypes
J. Virol.,
May 1, 2007;
81(9):
4904 - 4908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Campistol and F. P. Schena
Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors
Nephrol. Dial. Transplant.,
May 1, 2007;
22(suppl_1):
i17 - i22.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lambert, M. Gannage, A. Karras, M. Abel, C. Legendre, D. Kerob, F. Agbalika, P.-M. Girard, C. Lebbe, and S. Caillat-Zucman
Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma
Blood,
December 1, 2006;
108(12):
3871 - 3880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Rappocciolo, F. J. Jenkins, H. R. Hensler, P. Piazza, M. Jais, L. Borowski, S. C. Watkins, and C. R. Rinaldo Jr
DC-SIGN Is a Receptor for Human Herpesvirus 8 on Dendritic Cells and Macrophages
J. Immunol.,
February 1, 2006;
176(3):
1741 - 1749.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ribechini, C. Fortini, M. Marastoni, S. Traniello, S. Spisani, P. Monini, and R. Gavioli
Identification of CD8+ T Cell Epitopes within Lytic Antigens of Human Herpes Virus 8
J. Immunol.,
January 15, 2006;
176(2):
923 - 930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Dagna, F. Broccolo, C. T. Paties, M. Ferrarini, L. Sarmati, L. Praderio, M. G. Sabbadini, P. Lusso, and M. S. Malnati
A Relapsing Inflammatory Syndrome and Active Human Herpesvirus 8 Infection
N. Engl. J. Med.,
July 14, 2005;
353(2):
156 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Boulanger, L. Gerard, J. Gabarre, J.-M. Molina, C. Rapp, J.-F. Abino, J. Cadranel, S. Chevret, and E. Oksenhendler
Prognostic Factors and Outcome of Human Herpesvirus 8-Associated Primary Effusion Lymphoma in Patients With AIDS
J. Clin. Oncol.,
July 1, 2005;
23(19):
4372 - 4380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tomescu, W. K. Law, and D. H. Kedes
Surface Downregulation of Major Histocompatibility Complex Class I, PE-CAM, and ICAM-1 following De Novo Infection of Endothelial Cells with Kaposi's Sarcoma-Associated Herpesvirus
J. Virol.,
September 1, 2003;
77(17):
9669 - 9684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lindow, A. Nansen, C. Bartholdy, A. Stryhn, N. J. V. Hansen, T. P. Boesen, T. N. C. Wells, T. W. Schwartz, and A. R. Thomsen
The Virus-Encoded Chemokine vMIP-II Inhibits Virus-Induced Tc1-Driven Inflammation
J. Virol.,
July 1, 2003;
77(13):
7393 - 7400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Dourmishev, A. L. Dourmishev, D. Palmeri, R. A. Schwartz, and D. M. Lukac
Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis
Microbiol. Mol. Biol. Rev.,
June 1, 2003;
67(2):
175 - 212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Stebbing, S. Portsmouth, and B. Gazzard
How does HAART lead to the resolution of Kaposi's sarcoma?
J. Antimicrob. Chemother.,
May 1, 2003;
51(5):
1095 - 1098.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Stebbing, D. Bourboulia, M. Johnson, S. Henderson, I. Williams, N. Wilder, M. Tyrer, M. Youle, N. Imami, T. Kobu, et al.
Kaposi's Sarcoma-Associated Herpesvirus Cytotoxic T Lymphocytes Recognize and Target Darwinian Positively Selected Autologous K1 Epitopes
J. Virol.,
April 1, 2003;
77(7):
4306 - 4314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Jenkins, D. T. Rowe, and C. R. Rinaldo Jr.
Herpesvirus Infections in Organ Transplant Recipients
Clin. Vaccine Immunol.,
January 1, 2003;
10(1):
1 - 7.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. J. Wang, X.-L. Huang, G. Rappocciolo, F. J. Jenkins, W. H. Hildebrand, Z. Fan, E. K. Thomas, and C. R. Rinaldo Jr
Identification of an HLA A*0201-restricted CD8+ T-cell epitope for the glycoprotein B homolog of human herpesvirus 8
Blood,
May 1, 2002;
99(9):
3360 - 3366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wilkinson, A. Cope, J. Gill, D. Bourboulia, P. Hayes, N. Imami, T. Kubo, A. Marcelin, V. Calvez, R. Weiss, et al.
Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy
J. Virol.,
February 22, 2002;
76(6):
2634 - 2640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
